WeTrials
Recruiting

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

What is this study?

This study tests whether adding a new pill called inavolisib to standard antibody maintenance treatment (Phesgo, which combines trastuzumab and pertuzumab) can keep advanced HER2-positive breast cancer from growing for longer. It is for people whose tumor has a PIK3CA gene change, which about 1 in 4 people with this type of breast cancer have.

Who can participate?

You may be able to join if you have HER2-positive breast cancer that has spread or cannot be removed with surgery, your tumor has a PIK3CA mutation confirmed by the study's central testing, and you are starting your first treatment for advanced disease. The study includes this first phase of chemotherapy plus Phesgo, followed by maintenance. If your cancer came back after treatment for early-stage breast cancer, at least 6 months must have passed since that treatment ended. People with type 1 diabetes, type 2 diabetes that needs ongoing medicine, or prior treatment with certain targeted drugs (PI3K, AKT or mTOR inhibitors) for advanced disease cannot take part.

What will happen?

Participants will be randomly chosen to receive either the new study drug inavolisib or an inactive placebo, combined with the standard Phesgo treatment. You will be closely monitored by the study team throughout the process to check your health and safety.

Where and when?

The study is currently recruiting at 16 locations in the United States (Arizona, California, Maryland, Massachusetts, Michigan, North Carolina, Texas, Washington, and Washington, D.C.) and 7 in Canada (Alberta, New Brunswick, Ontario, and Quebec), among 89 recruiting sites worldwide. Your care team can help you find the closest participating site.

Key Points
  • 1Testing a new targeted drug called inavolisib for breast cancer
  • 2Requires a specific genetic mutation called PIK3CA in the tumor
  • 3Currently recruiting patients at multiple locations in the United States

Related video

HER2-Positive Metastatic Breast Cancer: FDA Approves an Add-On Pill for Maintenance

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Metastatic Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.